[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sclnow Biotechnology Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":113},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,65,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100370520","phase-1-the-safetyefficacy-study-of-human-umbilical-cord-mesenchymal-stem-cells-therapy-19isclife-ldp-for-lumbar-discogenic-pain-100370520",false,"NCT04104412","The Safety\u002FEfficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain","The Safety\u002FEfficacy Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Lumbar Discogenic Pain","Inclusion Criteria:\n\n1. age over 18\n2. refractory and persistent lumbago pain for more than 6 months, with\u002Fwithout radiation pain in lower limbs, and poor conservative treatment effect;\n3. the straight leg elevation test was 70 degrees negative;\n4. MRI of lumbar spine showed herniated disc \\\u003C 6 mm, no obvious compression of spinal cord and nerve roots; T2-weighted mri of the lumbar spine showed decreased single\u002Fmulti-segment signal (black disc sign) or High signal zone (HIZ) in the posterior part of the intervertebral disc annulus.\n5. clinical signs of nerve localization were consistent with MRI changes;\n6. subject gives informed consent and signs informed consent.\n\nExclusion Criteria:\n\n1. coagulation dysfunction or anticoagulant therapy;\n2. intervertebral space infection, puncture site infection or systemic infection;\n3. lumbago pain of non-spinal origin, such as sacroiliac joint origin pain;\n4. patients who have had open surgery or other disc treatments;\n5. imaging examination suggested disc prolapse, prolapse, spinal canal bone stenosis, etc.;\n6. patients with vital organ system dysfunction and tumor lumbar vertebra metastasis;\n7. subjects with high tumor markers (AFP\u002FCEA\u002FCA199\u002FCA125);\n8. the subject is pregnant or breastfeeding;\n9. subjects also receive other treatments that may affect the efficacy and safety of stem cells;\n10. failing to control alcohol and other substance abuse during the 6 months prior to enrollment and enrollment period;\n11. the subjects suffer from mental illness, or lack of understanding, communication and cooperation, and cannot be guaranteed to follow the study protocol;\n\nSubjects who are not willing to sign informed consent and are participating in other clinical trials or have participated in other clinical trials within 3 months;","ALL","18 Years",{"count":19,"type":20},242,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This experimental use umbilical cord mesenchymal stem cells in treatment of the early stage of lumbar discogenic pain (endogenous pain of the disc) to evaluate its safety and efficacy.\n\nThis experimental is mainly aimed at over 18years old people, regardless of gender, with refractory and persistent back pain for more than 6 months.\n\nThe efficacy and safety of mesenchymal stem cells (MSCS) were evaluated by low-temperature plasma ablation and intravertebral disc injection, which were divided into treatment group and control group.",[26],"Lumbar Discogenic Pain",[28,29],"lumbar discogenic pain","mesenchymal stem cell","RECRUITING","2026-04-22",{"date":33,"type":34},"2026-04-23","ACTUAL",{"date":36,"type":34},"2019-08-15",{"date":38,"type":20},"2027-06-30",{"name":40,"class":41},"Sclnow Biotechnology Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100349178","phase-1-huc-mesenchymal-stem-cells-19isclife-lc-in-the-treatment-of-decompensated-hepatitis-b-cirrhosishepatitis-b-cirrhosis-100349178","NCT03826433","hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis","Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosis","Inclusion Criteria:\n\n* Age 18-60 years old, gender not limited, body mass index (BMI) between 19-25 kg\u002Fm2, including boundary value;\n* The diagnosis of hepatitis B cirrhosis was in line with the 2015 American society of hepatology (AASLD) guidelines for the treatment of chronic hepatitis B, and the liver function grade was child-pugh B or child-pugh C, with a score range of 7-12 points, and Model for End-Stage Liver Disease score≤21 points.\n* Have not received stem cell therapy in the recent 6 months;\n* Subjects will be able to sign the informed consent in accordance with the study procedures and instructions.\n\nExclusion Criteria:\n\n* Insufficiency of vital organs, such as heart, kidney and lung;\n* End-stage cirrhosis with severe complications, including but not limited to: hepatic encephalopathy, gastrointestinal bleeding,Severe bleeding tendency, massive ascites, etc.\n* Concomitant peritonitis, pneumonia, or other types of infection not under control;\n* Have a history of severe allergic reaction or allergy to two or more kinds of food or medicine;\n* Positive serum HIV antibody and syphilis antibody;\n* Alpha fetoprotein\\>400ng\u002FmL with primary liver cancer or without imaging evidence;\n* Chronic liver disease and cirrhosis are caused by non-chronic hepatitis B virus infection, or other factors except chronic hepatitis B virus infection ;\n* Patients with severe mental illness and cognitive impairment;","60 Years",{"count":52,"type":20},20,[23],"1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.\n2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat.\n3. Explore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.",[56],"Hepatitis B",[58],"Hepatitis B Cirrhosis, mesenchymal stem cell",{"date":33,"type":34},{"date":61,"type":34},"2018-10-01",{"date":63,"type":20},"2027-12-31",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":50,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":83,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":90,"locationsCount":4},"100314814","phase-2-umbilical-cord-mesenchymal-stem-cells-therapy-19isclife-sa-for-patients-with-spinocerebellar-ataxia-100314814","NCT03378414","Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia","A Clinical Research on the Safety\u002FEfficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia","Inclusion Criteria:\n\n* Clinical and genomic test diagnoses as spinocerebellar ataxias (SCA) (include SCA 1, SCA 2, SCA 3, SCA 6), SARA (Scale for Assessment and Rating of Ataxia) score is 2-5, can complete 8-meter walking test（8MW）\n* Do not receive stem cells treatment in 6 months\n* Participants sign the consent form based on the experiment process and statement\n\nExclusion Criteria:\n\n* Cardiac, renal, hepatic insufficiency; total bilirubin is 1.5 times higher than normal value, aspartate transaminase（AST）or alanine aminotransferase（ALT）is 2.5 times higher than normal value\n* Hemogram: total white blood cells \\\u003C3.0 \\* 10\\^9 cells\u002FL, blood platelet \\\u003C75 \\* 10\\^9\u002FL, hemoglobin \\\u003C100g\u002FL\n* pneumonia, or severe infection\n* With severe allergic history\n* Brain organic disorder, like brain tumor\n* Serum with HIV, syphilis antibody positive\n* Severe mental disease, cognitive disorder patients\n* Other severe system or organ organic disease\n* Pregnant, breast feeding, or planning pregnant women\n* Participate other clinical experiments in 3 months\n* With some other conditions that doctor propose not to participate","16 Years",{"count":74,"type":20},45,[76],"PHASE2","The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.",[79,80,81,82],"Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia Type 3","Spinocerebellar Ataxia Type 6",[84],"Spinocerebellar Ataxia,Mesenchymal Stem Cells","NOT_YET_RECRUITING",{"date":33,"type":34},{"date":88,"type":20},"2026-12-31",{"date":63,"type":20},{"name":40,"class":41},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":112,"locationsCount":42},"100315173","phase-2-the-safetyefficacy-of-huc-mesenchymal-stem-cells19isclife-oa-therapy-for-patients-with-osteoarthritis-100315173","NCT03383081","The Safety\u002FEfficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis","A Clinical Research on the Safety\u002FEfficacy of Human Umbilical Cord Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis","Inclusion Criteria:\n\n* Diagnosis of Knee Osteoarthritis by Kellgren and Lawrence Grading Scale, classified with Grade 2-3\n* Confirm with cartilage injury,articular cartilage part or full-thickness injury, by MR (Magnetic Resonance)\n* Age \\\u003C70, no serious organ dysfunction\n* Over 2 years knee pain or no very effective with conservative treatments\n* Knee pain of VAS (visual analog scale score) is 4 or higher\n* Normal hepatic and renal function, no history of gout, rheumatoid arthritis, and autoimmune diseases, etc.\n* Understand and sign the consent form of this study\n\nExclusion Criteria:\n\n* Refuse to sign the consent form, or cannot keep follow-up visit\n* Age \\>70; Age \\\u003C70, but with multiple organ failure\n* Unstable vital signs (breath, blood pressure, pulse)\n* Combined with knee ligament (anterior and the posterior cruciate ligament, medial and lateral collateral ligament) rupture, laxity, etc.\n* Serious bleeding tendency, poor coagulation function (PTA \\\u003C35%)\n* Pregnant or breast feeding women, or positive pregnancy test in 7 days before treatment\n* Participate other clinical experiments in 3 months\n* With progressing malignant tumor\n* Combined with shock and critically ill patients\n* With mental disease, cannot\n* With history of knee joint infection, surgery, and radiotherapy\n* With immunosuppressive agents treatment in 6 weeks\n* Injection with hormones and sodium hyaluronate in joint in 3 months\n* Overweight expressed as body mass index (BMI) \\>35\n* With skin disease around knee joint\n* With Immunodeficiency disease, including long term use immunosuppressive agents patients\n* Combined with serious infection\n* With some other conditions that doctor propose not to participate","70 Years",{"count":100,"type":20},60,[76],"The purpose of this study is verify the efficacy and safety of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition, provide basis for exploring the treatment regimen of UC-MSC therapy in different degree of cartilage defect disease",[104],"Osteoarthritis, Knee",[106],"osteoarthritis, mesenchymal stem cell","2025-12-02",{"date":109,"type":34},"2025-12-04",{"date":61,"type":34},{"date":88,"type":20},{"name":40,"class":41},""]